Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Clean and Really focus on Your Lab Precious stone - 2Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- 34 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- 4Consumer outlook on UK economy falls to two-year low
- 5Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
- Pick Your Favored kind of soup
- The Incomparable Advanced cameras: Which One Will Win?
- Geomagnetic storm grounds launch of Mars space weather satellites
- Auschwitz Committee wants German auction of Holocaust items scrapped
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- Step by step instructions to Pick A Keep money with High Fixed Store Loan costs
- Why this Iranian island looks like Mars after it rains
- Finding the Universe of Computer generated Reality: Individual Encounters
- How Mars' ancient lakes grew shields of ice to stay warm as the Red Planet froze
